{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:37:03Z","timestamp":1783654623952,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020320","name":"Institut pour la Recherche en Sant\u00e9 Publique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.058","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:47:40Z","timestamp":1729684060000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?"],"prefix":"10.1016","volume":"80","author":[{"given":"Thomas","family":"Soeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.058_bib0230","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.drugalcdep.2009.08.011","article-title":"Monitoring risk: post marketing surveillance and signal detection","volume":"105","author":"Dart","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.058_bib0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMp1806486","article-title":"The FDA and the next wave of drug abuse\u00a0\u2014\u00a0proactive pharmacovigilance","volume":"379","author":"Throckmorton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.10.058_bib0240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"Le m\u00e9susage du fentanyl en France\u00a0: 2010\u00a0\u00e0 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0245","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.058_bib0250","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013\u00a0to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0255","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2515\/therapie:2004100","article-title":"Utilisation des bases de donn\u00e9es de l\u2019Assurance maladie par les Centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance\u00a0: exemples, int\u00e9r\u00eats et perspectives","volume":"59","author":"Micallef","year":"2004","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.therap.2018.09.078","article-title":"Interest of large electronic health care databases in addictovigilance: lessons from 15\u00a0years of pharmacoepidemiological contribution","volume":"74","author":"Dupui","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2024.10.053","article-title":"From the first pilot initiatives in the early 1990s to the national OSIAP survey in the 2020s: more than 30\u00a0years of insight in medication diversion phenomenon in France","volume":"80","author":"Lapeyre-Mestre","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2024.10.054","article-title":"Monitoring misuse and abuse of psychoactive substances in France: insights from substance abuse treatment facilities through the OPPIDUM program","volume":"80","author":"Lacroix","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0275","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.therap.2024.10.059","article-title":"DRAMES and DTA registers: complementary tools for monitoring drug-related deaths in France","volume":"80","author":"Revol","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0280","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.therap.2024.10.055","article-title":"ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001","volume":"80","author":"Perri-Pland\u00e9","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0285","doi-asserted-by":"crossref","first-page":"102297","DOI":"10.1016\/j.legalmed.2023.102297","article-title":"Assessment of 19\u00a0years of a prospective national survey on drug-facilitated crimes in France","volume":"65","author":"Djezzar","year":"2023","journal-title":"Leg Med (Tokyo)"},{"key":"10.1016\/j.therap.2024.10.058_bib0290","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0295","first-page":"151","article-title":"\u00c9tude de la \u00ab\u00a0m\u00e9thadone relais\u00a0\u00bb dans le d\u00e9partement des Bouches-du-Rh\u00f4ne","volume":"31","author":"Pradel","year":"2001","journal-title":"BEH"},{"key":"10.1016\/j.therap.2024.10.058_bib0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0376-8716(01)00161-2","article-title":"Buprenorphine prescription by general practitioners in a French region","volume":"65","author":"Thirion","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.058_bib0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.drugalcdep.2003.08.005","article-title":"Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users","volume":"72","author":"Lapeyre-Mestre","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.058_bib0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/fcp.12696","article-title":"Use of the French national health insurance information system for research in the field of mental health: systematic review and perspectives","volume":"36","author":"Revet","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0315","doi-asserted-by":"crossref","first-page":"1595953","DOI":"10.1080\/20016689.2019.1595953","article-title":"Characteristics of doctor-shoppers: a systematic literature review","volume":"7","author":"Biernikiewicz","year":"2019","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.therap.2024.10.058_bib0320","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/pm\/pnab344","article-title":"Defining \u201cDoctor Shopping\u201d with dispensing data: a scoping review","volume":"23","author":"Delcher","year":"2022","journal-title":"Pain Med"},{"key":"10.1016\/j.therap.2024.10.058_bib0325","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.10.058_bib0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1393","article-title":"Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims","volume":"348","author":"Jena","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2024.10.058_bib0335","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamainternmed.2013.12711","article-title":"High-risk use by patients prescribed opioids for pain and its role in overdose deaths","volume":"174","author":"Baumblatt","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2024.10.058_bib0340","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/add.16261","article-title":"Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: a nation-wide, repeated cross-sectional study","volume":"118","author":"Soeiro","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.10.058_bib0345","doi-asserted-by":"crossref","first-page":"640120","DOI":"10.3389\/fpsyt.2021.640120","article-title":"Early detection of prescription drug abuse using doctor shopping monitoring from claims databases: illustration from the experience of the French Addictovigilance Network","volume":"12","author":"Soeiro","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.058_bib0350","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2515\/therapie\/2011037","article-title":"Evolution of opioids reimbursement since 2004\u00a0from the National Database of the General Health Insurance System","volume":"66","author":"Pauly","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0355","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.13564","article-title":"Trends in analgesic consumption in France over the last 10\u00a0years and comparison of patterns across Europe","volume":"84","author":"Hider-Mlynarz","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0360","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejp.1291","article-title":"Prescription opioid analgesic use in France: trends and impact on morbidity\u2013mortality","volume":"23","author":"Chenaf","year":"2019","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2024.10.058_bib0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2515\/therapie\/2011004","article-title":"Quel(s) antalgique(s) apr\u00e8s le retrait du dextropropoxyph\u00e8ne\u00a0? Enqu\u00eate aupr\u00e8s de m\u00e9decins g\u00e9n\u00e9ralistes de la r\u00e9gion Midi-Pyr\u00e9n\u00e9es","volume":"66","author":"Bismuth","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0370","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcp.14415","article-title":"Ten-year trend of opioid and nonopioid analgesic use in the French adult population","volume":"87","author":"Daveluy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0375","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/fcp.12962","article-title":"Analgesic switching in chronic users of dextropropoxyphene in France","volume":"38","author":"Daveluy","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0380","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","article-title":"Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia","volume":"59","author":"Holm","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2024.10.058_bib0385","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0390","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10550887.2014.882725","article-title":"An update on zolpidem abuse and dependence","volume":"33","author":"Victorri-Vigneau","year":"2014","journal-title":"J Addict Dis"},{"key":"10.1016\/j.therap.2024.10.058_bib0395","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0400","doi-asserted-by":"crossref","first-page":"e0228495","DOI":"10.1371\/journal.pone.0228495","article-title":"Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: a SNDS database nested cohort study","volume":"15","author":"Caillet","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2024.10.058_bib0405","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1370\/afm.2556","article-title":"Impact of secured prescription implementation for zolpidem on hypnotics use in France: a time-series analysis on national data","volume":"18","author":"Rousselot","year":"2020","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.therap.2024.10.058_bib0410","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-019-02737-7","article-title":"Consequences of the new zolpidem prescription regulations: a cohort study from the French national healthcare database","volume":"76","author":"Touchard","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0415","doi-asserted-by":"crossref","first-page":"e027443","DOI":"10.1136\/bmjopen-2018-027443","article-title":"French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol","volume":"9","author":"G\u00e9rardin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.therap.2024.10.058_bib0420","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1111\/bcp.14753","article-title":"Change in the regulatory framework for zolpidem: what is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study","volume":"87","author":"Istvan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0425","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/14740338.2022.2047930","article-title":"Did the pattern of use of zolpidem change since the enforcement of a new prescription rule? A latent class analysis using the French health insurance database","volume":"21","author":"Istvan","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2024.10.058_bib0430","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2515\/therapie:2003069","article-title":"Impacts de la nouvelle r\u00e9glementation du flunitraz\u00e9pam sur la consommation d\u2019hypnotiques","volume":"58","author":"Victorri-Vigneau","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2515\/therapie\/2015011","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0440","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"D\u00e9tection des signaux du r\u00e9seau fran\u00e7ais d\u2019addictovigilance\u202f: m\u00e9thodes innovantes d\u2019investigation, illustrations et utilit\u00e9 pour la sant\u00e9 publique","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.058_bib0445","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/bcp.13272","article-title":"Early signal of diverted use of tropicamide eye drops in France: early signal of diverted use of tropicamide eye drops in France","volume":"83","author":"Pont\u00e9","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.058_bib0450","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann","year":"2013","journal-title":"Pain Physician"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:47:07Z","timestamp":1762220827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001744"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.058","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}